Moreover, we found that the association of serum adiponectin and the risk of CV events is dramatically altered at eGFR 70–75 ml/min/1.73 m2 (Supplementary Figure S3), suggesting that adiponectin paradox in patients with CKD is already present even in early stages. Here, ADIPOQ is linked to chronic kidney disease.